Latest Articles
-
Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns
We believe that pharmaceutical giants Merck stock (NYSE: MRK) and Pfizer stock (NYSE: PFE) will likely offer similar returns over the next three years. Although Merck is trading at a comparatively higher valuation of 4.9x trailing revenues ...
-
Company Of The Day: Merck
What? Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin. Why? Keytruda will see patents start to expire in 2028. Merck believes that the new formulation h...
-
Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
Merck stock (NYSE: MRK) is up 12% in a month, outperforming the broader S&P500 index, up 5%. The rise in MRK stock can be attributed to the upbeat Q3 earnings it reported in late October. Its top and bottom line were well above our estimat...
-
Will Merck Stock Rise After Its Q3 Results?
Merck (NYSE: MRK) is scheduled to report its Q3 2022 results on Thursday, October 27. We expect the company to post mixed results, with revenue falling short and earnings slightly above the consensus estimate. Although the company should benefi...
-
Merck Stock Is Likely A Better Pick Over Its Peer
We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. Investors have assigned a higher P/S mu...
-
Is Humira Maker A Better Bet Over Merck Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its peer Merck stock (NYSE: MRK), given its better growth prospects. Both companies are comparable in valuation, with AbbVie trading at 4.2x, trailing revenues, and M...
-
Should You Buy Merck Stock After An Upbeat Q2?
Merck stock (NYSE: MRK) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, MRK stock has seen a fall of around 4% in a week, with rising concerns over the drug pricing bill. A...
-
Will Merck Stock Rise After Its Q2 Results?
Merck (NYSE: MRK) is scheduled to report its Q2 2022 results on Thursday, July 28. We expect the company to have a robust Q2, with revenue falling in-line and earnings expected to be slightly above the consensus estimates, driven by a continued...
-
What’s Happening With Merck Stock?
Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. There are a coup...
-
Is There A Better Pick Over Merck Stock In Animal Health Space?
We think that Zoetis stock (NYSE: ZTS) currently is a better pick compared to its peer Merck stock (NYSE: MRK), despite Zoetis being the more expensive of the two, trading at 9x trailing revenues, compared to just 4x for Merck. This valuati...
-
Will Merck Stock Rise After Its Q1 Results?
Merck (NYSE: MRK) is scheduled to report its Q1 2022 results on Thursday, Apr 28. We expect MRK stock to trend higher in the near term due to a strong Q1, with revenue falling in-line and earnings expected to be comfortably above the consensus ...
-
Company Of The Day: Merck
What? Merck (NYSE:MRK) and AstraZenica’s cancer drug Lynparza has been approved by the U.S. FDA to treat patients with early-stage breast cancer with certain mutations. So What? Merck’s alliance revenue from Lynparza stood at abou...
-
What’s Next For Merck Stock After A 6% Fall In A Month?
The stock price of Merck (NYSE: MRK) has seen a fall of 6% over the last month, while it is down 1% year-to-date. This marks a better performance than the broader markets, with the S&P500 down 6% over the last month but down 10% so far this...
-
Will Merck Stock Rise After Its Q4 Results?
Merck (NYSE: MRK) is scheduled to report its Q4 2021 results on Thursday, Feb 3. We expect MRK stock to trend higher in the near term due to an upbeat Q4, with revenue and earnings expected to be comfortably above the consensus estimates, drive...
-
Here’s A Better Pharmaceutical Pick Over Merck Stock
We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trail...
